Pular para o conteúdo principal
Ranking Invest

RNAC - Cartesian Therapeutics, Inc.

Segmento: HealthcareSelecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Análise Ranking Invest

Valor de Mercado
$ 196.05 Mi
IVR
-2.71Índice proprietário de comparação relativa: -2,71.
IVR2
-2.12Leitura proprietária complementar: -212%.
MLL
-2.12Leitura proprietária complementar: -212%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

-$ 125.23 Mi

Dívida Líquida

-$ 94.75 Mi

L4T

-$ 151.89 Mi

MM4T

-16987.99%

Indicadores Básicos

ROE

121.29%

Índices de Previsibilidade

Receita Líquida

G0.86

Lucro

E1.02

Margem

E1.30

Índices de Tendência

Receita Líquida

E-6.71

Lucro

E-2.99

Margem

E-4.14

Índices de Endividamento

DIV/PAT

0.76

DIV/L4T

0.62

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.